<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>GEN &#8211; Genetic Engineering and Biotechnology News</title>
	<atom:link href="https://www.genengnews.com/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.genengnews.com/</link>
	<description>Leading the way in life science technologies</description>
	<lastBuildDate>Mon, 16 Nov 2026 20:59:11 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://www.genengnews.com/wp-content/uploads/2018/10/cropped-GEN_App_Icon_1024x1024-1-150x150.png</url>
	<title>GEN &#8211; Genetic Engineering and Biotechnology News</title>
	<link>https://www.genengnews.com/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Gut Microbome and Bile Acid Modification Linked with Longevity</title>
		<link>https://www.genengnews.com/topics/translational-medicine/gut-microbome-and-bile-acid-modification-linked-with-longevity/</link>
		
		<dc:creator><![CDATA[Sophia Ktori]]></dc:creator>
		<pubDate>Mon, 16 Nov 2026 20:59:11 +0000</pubDate>
				<category><![CDATA[Drug Discovery]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Topics]]></category>
		<category><![CDATA[Translational Medicine]]></category>
		<guid isPermaLink="false">https://www.genengnews.com/?p=340674</guid>

					<description><![CDATA[<p>Researchers studying how gut microbes modify bile acids have identified changes in the metabolic activity of the gut microbiome associated with exceptional longevity in humans, and found that amplifying the same activity with engineered bacteria improved metabolic health in aged mice.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/gut-microbome-and-bile-acid-modification-linked-with-longevity/">Gut Microbome and Bile Acid Modification Linked with Longevity</a> appeared first on <a href="https://www.genengnews.com">GEN - Genetic Engineering and Biotechnology News</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Researchers from the University of California San Diego have identified changes in the metabolic activity of the gut microbiome associated with exceptional longevity in humans, and found that amplifying the same activity with engineered bacteria improved metabolic health in aged mice.</p>
<p>“Many studies of aging focus on what goes wrong as we get older, but our findings suggest that some changes in the gut microbiome may actually represent the body’s attempt to preserve metabolic health,” said Amir Zarrinpar, MD, PhD, Stuart and Barbara L. Brody Endowed Chair in Circadian Biology and Medicine, and professor of medicine at UC San Diego School of Medicine. “If we can identify those beneficial functions and safely strengthen them, we may eventually be able to develop new ways to promote healthier aging.”</p>
<aside class="my-8" style="clear:both" aria-label="Advertisement"><span id='malgam_render_3' data-render-ad='3'></span></aside>
<p>Zarrinpar is senior and corresponding author of the researchers’ published paper in <em>Cell Metabolism</em>, titled “<a href="https://www.cell.com/cell-metabolism/fulltext/S1550-4131(26)00453-5" target="_blank" rel="noopener">Microbial bile acid deconjugation counters metabolic decline in aging</a>.”</p>
<p>For their reported study the researchers focused on how gut microbes modify bile acids. Gut bacteria produce enzymes called bile salt hydrolases (BSH) that chemically modify bile acids, allowing them to influence pathways involved in metabolism, inflammation and the body&#8217;s internal clock. “Gut microbes modify bile acids through several reactions, including deconjugation by bile salt hydrolase (BSH),” the team wrote. “Deconjugated bile acids can regulate host gene expression and signaling pathways, including those involved in metabolism, inflammation, and circadian rhythms.”</p>
<p>The gut microbiome—the community of bacteria and other microbes living in the digestive tract—changes throughout life and plays an important role in metabolism, inflammation, and other aspects of health. Previous research has linked age-related changes in the microbiome with frailty, chronic inflammation, and disease, while other studies have found distinctive microbiome features among people who age exceptionally well.</p>
<aside class="my-8" style="clear:both" aria-label="Advertisement"><span id='malgam_render_4' data-render-ad='4'></span></aside>
<p>The researchers first studied young and aged mice and found that aging was associated with increased microbial activity related to BSH and greater bile acid modification. To determine whether a similar pattern occurred in humans, they reanalyzed publicly available data from a human aging cohort. The analysis included bile acid measurements from 48 young adults, 107 older adults, and 125 centenarians. The centenarian group showed higher ratios of certain modified bile acids than both younger groups.</p>
<p>Analysis of microbiome data also found greater abundance of a gene associated with BSH activity among centenarians compared with the older adult group. “Individuals with exceptional longevity show a similar bile acid deconjugation signature, suggesting an association with resilient or exceptional aging,” the team pointed out.</p>
<p>They then asked whether enhancing this microbial function could produce health benefits. The researchers engineered a strain of bacteria native to the gut to continuously produce BSH, and introduced the bacteria into 82-week-old mice—considered aged. A single treatment resulted in stable colonization, allowing the bacteria to persist and produce the enzyme over time.</p>
<p>Approximately 20 weeks after treatment, mice receiving the BSH-producing bacteria had significantly improved insulin sensitivity and modestly improved glucose tolerance compared with mice receiving a matched control bacterium. By 32 weeks, the treated mice also showed changes consistent with lower body weight and fat mass and greater lean mass. Other findings pointed to increased use of fat for energy, improved mitochondrial function, and changes in gene activity related to inflammation and the body’s internal clock. “Using engineered native bacteria, we further increased luminal BSH activity in aged mice and improved insulin sensitivity, accompanied by supportive changes in body composition and other metabolic readouts,” the investigators commented.</p>
<p>The results do not show that the microbial changes caused exceptional longevity in humans or that the engineered bacteria can extend lifespan. The authors note that centenarians and aged mice are not directly comparable, and the human findings provide supporting rather than definitive evidence. “We also acknowledge that aged mice and individuals with exceptional longevity are not directly equivalent and therefore consider the centenarian data corroborative rather than definitive evidence,” they stated. “From this perspective, increased BSH activity may serve as a marker of, or potential contributor to, metabolic resilience during aging. More studies in people will be needed to determine whether increased BSH activity is a marker of healthy aging, a contributor to it, or both.&#8221;</p>
<p>The study also points toward a broader possibility: rather than attempting to replace the entire gut microbiome, researchers may eventually be able to identify beneficial microbial functions and selectively enhance them. In their paper they noted, “Together, these findings suggest that elevated BSH activity may have a protective role during aging. They challenge the view that age-related changes in bile acid biotransformations are uniformly detrimental, highlighting microbial bile acid modulation as a potential strategy to improve late-life metabolic health.”</p>
<aside class="my-8" style="clear:both" aria-label="Advertisement"><span id='malgam_render_5' data-render-ad='5'></span></aside>
<p>Future studies will investigate how different forms of BSH affect bile acid metabolism, inflammation, energy use, and other aspects of aging, as well as whether the approach works similarly in females, given established differences in aging based on sex.</p>
<p>“The goal isn’t simply to live longer—it’s to understand the biology that allows some people to remain resilient as they age,” said Zarrinpar. “The microbiome gives us an intriguing opportunity because, unlike many aspects of aging, it may be something we can modify. This study gives us a starting point for asking whether beneficial microbial functions can be amplified to help preserve metabolic health later in life.”</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/gut-microbome-and-bile-acid-modification-linked-with-longevity/">Gut Microbome and Bile Acid Modification Linked with Longevity</a> appeared first on <a href="https://www.genengnews.com">GEN - Genetic Engineering and Biotechnology News</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Single-Cell Method Reveals On- and Off-Target Effects of Cas9 Edits on Gene Expression</title>
		<link>https://www.genengnews.com/topics/genome-editing/single-cell-method-reveals-on-and-off-target-effects-of-cas9-edits-on-gene-expression/</link>
		
		<dc:creator><![CDATA[Uduak Thomas]]></dc:creator>
		<pubDate>Mon, 16 Nov 2026 10:00:23 +0000</pubDate>
				<category><![CDATA[Genome Editing]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[OMICs]]></category>
		<category><![CDATA[Topics]]></category>
		<guid isPermaLink="false">https://www.genengnews.com/?p=340626</guid>

					<description><![CDATA[<p>A new method called Superb-seq pairs Cas9 editing with single-cell RNA sequencing to show which edits, including off-target ones, occur in each cell and how they alter gene expression, offering a clearer view of genome editing’s potential consequences.</p>
<p>The post <a href="https://www.genengnews.com/topics/genome-editing/single-cell-method-reveals-on-and-off-target-effects-of-cas9-edits-on-gene-expression/">Single-Cell Method Reveals On- and Off-Target Effects of Cas9 Edits on Gene Expression</a> appeared first on <a href="https://www.genengnews.com">GEN - Genetic Engineering and Biotechnology News</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p><span style="font-weight: 400;">Scientists at the Salk Institute and their collaborators have published a paper in </span><i><span style="font-weight: 400;">Nature Methods</span></i><span style="font-weight: 400;"> describing Superb-seq, a method of reading out both on and off target edits made by CRISPR/Cas9 technology. According to the developers, the tool makes it possible to read changes made by CRISPR at single-cell resolution to identify unwanted edits and assess how those edits change gene activity. Their paper is titled “</span><a href="https://www.nature.com/articles/s41592-026-03319-z" target="_blank" rel="noopener"><span style="font-weight: 400;">Joint single-cell capture of Cas9 edits and transcriptomes reveals on- and off-target effects on gene expression</span></a><span style="font-weight: 400;">.” </span></p>
<p><span style="font-weight: 400;">“What really inspired Superb-seq was a frustration with the existing state of affairs,” said Graham McVicker, PhD, senior author of the study and an associate professor at Salk. “We knew there were problems with CRISPR making unwanted edits, but also there was no good way to see what those edits were and how they affected the cell—what we wanted to see was invisible using current technologies.”</span></p>
<p><span style="font-weight: 400;">According to the developers, Superb-seq is able to show where unwanted edits are located as well as how those edits disrupt key genes that protect against unhealthy cellular states. Specifically, Superb-seq integrates Cas9 editing, T7 transcription, and single-cell RNA sequencing to capture single-cell edits and their impact on gene expression. The team has tested it on 34,000 cells from three different cell lines. “There are some people that have worked on this off-target issue before that have an awareness of how bad it is, but for many people that pick up CRISPR to use in the lab, the extent of this problem will really come as a surprise,” McVicker said. “I knew off-targets were an issue, but they were far more frequent than I was expecting.”</span></p>
<p><span style="font-weight: 400;">Using seven guide RNAs to target genes in one group of 10,000 human leukemia cells grown in the lab, Superb-seq detected 43 edit sites, including 36 of which were off-target, and 5,761 edited cells. Additionally, Superb-seq detected gene expression changes caused by genome edits that are invisible to existing edit detection methods. It also improved interpretation of the effect of edits compared to Perturb-seq, which reads out gene expression and guide RNAs but not the resulting edits.</span></p>
<p><span style="font-weight: 400;">The Salk scientists anticipate that Superb-seq could support applications in basic research, drug development, and personalized medicine. For existing studies that have used CRISPR to study different aspects of biology, “Superb-seq could reveal the extent to which off-target edits color all those findings,” said Michael Lorenzini, PhD, one of the first authors on the paper and a staff scientist in McVicker’s lab. Beyond basic discovery, “our tool could be immensely helpful in establishing the safety of genome therapy candidates early on in development. Superb-seq could be used to profile candidates and learn what their off-target edits are, as well as their effects,” he added. </span></p>
<p><span style="font-weight: 400;">The team also envisions Superb-seq as a valuable tool for generating training data to improve the accuracy of machine learning models of cellular function. McVicker, Lorenzini, and another co-author, Brad Balderson, PhD, have filed a patent for Superb-seq. </span></p>
<p>The post <a href="https://www.genengnews.com/topics/genome-editing/single-cell-method-reveals-on-and-off-target-effects-of-cas9-edits-on-gene-expression/">Single-Cell Method Reveals On- and Off-Target Effects of Cas9 Edits on Gene Expression</a> appeared first on <a href="https://www.genengnews.com">GEN - Genetic Engineering and Biotechnology News</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>StockWatch: Amid Nvidia Turmoil, What Happens to Its Life Sciences Collaborations?</title>
		<link>https://www.genengnews.com/topics/artificial-intelligence/stockwatch-amid-nvidia-turmoil-what-happens-to-its-life-sciences-collaborations/</link>
		
		<dc:creator><![CDATA[Alex Philippidis]]></dc:creator>
		<pubDate>Sun, 15 Nov 2026 21:57:19 +0000</pubDate>
				<category><![CDATA[Artificial Intelligence]]></category>
		<category><![CDATA[GEN Edge]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Topics]]></category>
		<guid isPermaLink="false">https://www.genengnews.com/?p=340560</guid>

					<description><![CDATA[<p>While Nvidia doesn’t develop new therapies, instruments, or reagents, its AI technology powers numerous collaborations with biopharma and lab tools giants stretching back at least five years.</p>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/stockwatch-amid-nvidia-turmoil-what-happens-to-its-life-sciences-collaborations/">StockWatch: Amid Nvidia Turmoil, What Happens to Its Life Sciences Collaborations?</a> appeared first on <a href="https://www.genengnews.com">GEN - Genetic Engineering and Biotechnology News</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Shakespeare and Greek mythology have met their match with the dramatic personal downfall story that culminated in Jensen Huang’s sudden resignation as CEO of <strong>Nvidia (Nasdaq: NVDA)</strong> amid turmoil caused by up to three reported extramarital affairs. While Nvidia doesn’t develop new therapies, instruments, or reagents, its AI technology powers numerous collaborations with biopharma and lab tools giants <a href="https://www.genengnews.com/gen-edge/from-model-to-molecule-nvidia-doubles-down-on-ai-drug-discovery/">stretching back at least five years</a>.</p>
<p>Nvidia’s board named Colette Kress as interim CEO. Kress has served as executive vice president and CFO since joining the company in 2013.</p>
<p>“The Board has full confidence in Colette and the leadership team, and we expect the company’s operations, customer commitments, and product roadmap to continue without interruption,” Harvey C. Jones, an Nvidia board member since 1993 who was named chair on Thursday, said in a statement. Jones is an entrepreneur, technology executive, and active venture investor who had served as CEO and executive chairman of silicon design provider Synopsys.</p>
<p>The first reported affair raised national security issues after Huang disclosed in a <a href="https://nvidianews.nvidia.com/news/a-message-to-our-company">letter to Nvidia employees made public November 8</a> that he had conducted an extramarital relationship with Alice Huang (no relation), founder of Megaspeed International, an Nvidia customer and Singapore-based provider of cloud computing and AI infrastructure services. The disclosure touched off an investigation by Nvidia’s board into Jensen Huang&#8217;s relationship with Alice Huang, who according to U.S. intelligence officials may have passed along sensitive information to China&#8217;s Ministry of State Security; Beijing has denied she carried out any intelligence activity for China.</p>
<figure id="attachment_340640" aria-describedby="caption-attachment-340640" style="width: 225px" class="wp-caption alignleft"><img fetchpriority="high" decoding="async" class="size-medium wp-image-340640" src="https://www.genengnews.com/wp-content/uploads/2026/11/Jensen-Huang-GTC-2024-031924__8fe9c08a-2e0e-4991-b7f5-8c6dbde0ae73-225x300.jpg" alt="Jensen Huang" width="225" height="300" srcset="https://www.genengnews.com/wp-content/uploads/2026/11/Jensen-Huang-GTC-2024-031924__8fe9c08a-2e0e-4991-b7f5-8c6dbde0ae73-225x300.jpg 225w, https://www.genengnews.com/wp-content/uploads/2026/11/Jensen-Huang-GTC-2024-031924__8fe9c08a-2e0e-4991-b7f5-8c6dbde0ae73-768x1024.jpg 768w, https://www.genengnews.com/wp-content/uploads/2026/11/Jensen-Huang-GTC-2024-031924__8fe9c08a-2e0e-4991-b7f5-8c6dbde0ae73-1152x1536.jpg 1152w, https://www.genengnews.com/wp-content/uploads/2026/11/Jensen-Huang-GTC-2024-031924__8fe9c08a-2e0e-4991-b7f5-8c6dbde0ae73.jpg 1440w" sizes="(max-width: 225px) 100vw, 225px" /><figcaption id="caption-attachment-340640" class="wp-caption-text">Nvidia co-founder Jensen Huang addresses the NVIDIA GTC 2024 conference in San Jose, CA. Huang Huang resigned as CEO on Thursday amid turmoil caused by up to three reported extramarital affairs. [Alex Philippidis]</figcaption></figure>
<p>Three days later on Wednesday, <em>The New York Times</em> cited five unnamed sources in reporting that Huang had an extramarital relationship with an Nvidia executive identified by the newspaper as Kimberly Powell, who as vice president of healthcare and life sciences served as Nvidia’s top executive overseeing its hardware and software platforms for accelerated computing, AI, and visualization in applications ranging from drug discovery to medical imaging and healthcare analytics. The following day, Reuters cited two unnamed sources in reporting an affair between Jensen Huang and a second Nvidia employee whom it did not name.</p>
<p>“OK, this is very, very, very sad, and may and will have dramatic consequences for the entire industry,” Alex Zhavoronkov, PhD, the founder, CEO, and CBO of <strong>Insilico Medicine</strong> <strong>(Hong Kong Exchange: 3696)</strong>,” <a href="https://x.com/biogerontology/status/2120817926005571686">posted Thursday on X</a>. “Now, half of the massively overvalued AI drug discovery startups with no productivity metrics, no drugs, and no long-term moat will not be able to fundraise from Nvidia for a while.”</p>
<h4><strong>Bedroom bubble burst</strong></h4>
<p>“Who knew that the AI bubble would burst in the employee bedroom…,” added Zhavoronkov, who also leads Insilico’s board as chairman and executive director. He added in a <a href="https://x.com/biogerontology/status/2120875228981010472">separate post</a>: “Let&#8217;s hope it all settles without too much drama and Jensen keeps working hard (and probably even harder).”</p>
<p>On Friday, Zhavoronkov recalled how during his company’s struggling early years, Jensen Huang <a href="https://x.com/biogerontology/status/2121323131801333922">recorded a video</a> marking the launch of Insilico&#8217;s Pharma.AI drug discovery platform: &#8220;When Jensen recorded this video in 2022 2 weeks before the launch of consumer ChatGPT, I honestly could not hold my tears. When I watched it today, I could not hold my tears either.&#8221;</p>
<p>&#8220;Some of my followers on LinkedIn are even celebrating. There is nothing to celebrate. This is a real tragedy and it will have industry-scale consequences. I truly hope that Jensen comes back in some capacity,&#8221; Zhavoronkov added. &#8220;To all my friends at NVIDIA—please stay strong and let&#8217;s work together to solve aging. Support Jensen and his wonderful family. We respect you and love you even though we [are] not a buyer of chips.&#8221;</p>
<p>The reported affairs and resignation of Huang sent Nvidia shares sinking this past week. The declines compounded a month-long Nvidia stock slide stemming from investor worries about whether the spending of tech giants on AI infrastructure will result in <span data-subtree="aimfl,mfl">sustainable cash flow, profits, and revenue quickly enough to justify the expense. </span>Those fears have caused Nvidia stock to <span style="color: #ff0000;"><strong>nosedive</strong><strong> 32% </strong></span>since hitting a record closing price of $239.24 on October 6.</p>
<p>Nvidia shares began the week <span style="color: #ff0000;"><strong>slipping 4%</strong></span> on November 9, from $186.64 to $178.67.  Shares <span style="color: #ff0000;"><strong>slid another 5.5%</strong></span> Tuesday to $168.89, <span style="color: #008000;"><strong>rebounded nearly 3%</strong></span> Wednesday to $173.73, then <span style="color: #ff0000;"><strong>fell again 4%</strong> </span>Thursday to $166.19 after starting that day <span style="color: #ff0000;"><strong>tumbling 14%</strong></span> following Huang&#8217;s resignation. Shares finished this past week <span style="color: #ff0000;"><strong>dipping 2% </strong></span>Friday, closing at $162.85—a <strong><span style="color: #ff0000;">five-day decline of 12.75%</span></strong><strong><span style="color: #ff0000;">.</span></strong></p>
<p>“The stakes behind Huang’s resignation reveal the murky waters that businesses using AI are swimming in,” Asa Hiken, senior analyst with Emarketer, wrote in a commentary posted on the website of the market research and digital intelligence company. &#8220;On the surface, AI is a tool for powering productivity, creative production, or novel customer experiences, but in the depths it’s a swelling geopolitical powder keg. Disentangling these two sides of the technology is impossible.&#8221;</p>
<p>Stacy Rasgon, managing director and senior analyst, U.S. semiconductors and semiconductor capital equipment at Bernstein Research, cautioned that Nvidia&#8217;s challenges have not ended with the resignation of Jensen Huang.</p>
<h4><strong>&#8220;Considerable uncertainty&#8221;</strong></h4>
<p>“We see considerable uncertainty around further news flow that is probably going to be coming down the pipe, as well as the ability of any new CEO to truly fill Jensen’s shoes given how tightly he managed the direction of the business and its relationships with customers, suppliers, employees, and the broader industry ecosystem,” Rasgon wrote in a research note, as reported by <em>Bloomberg News</em>.</p>
<p><span data-subtree="aimfl,mfl">Nvidia and its venture arm NVentures </span>participated in 122 startup funding deals in 2026 as of Friday, according to Crunchbase, while PitchBook counted 67 such deals in 2025 and 54 in 2024. Given Nvidia&#8217;s investment in AI startups, Rasgon wrote: “We wonder what will happen to the company’s myriad of investments in the space, various backstops and residual guarantees.&#8221; Rasgon downgraded Bernstein&#8217;s rating on Nvidia stock to “Market Perform” and lowered the firm&#8217;s price target to $200.</p>
<p>“Our gut tells us that we probably haven’t yet fully probed the depths of what might be found here,” Rasgon commented, adding: &#8220;We’ve had enough, and prefer to watch from the sidelines.”</p>
<p>A recent example of Nvidia&#8217;s life sciences footprint came earlier this month when <strong>10x Genomics (Nasdaq: TXG),</strong> a developer of scalable single-cell and spatial biology platforms, launched Sentira Single Cell, a cloud-based agentic analysis application for users of the company&#8217;s Chromium single-cell platform, powered by the Claude models of <strong>Anthropic (Nasdaq: ANT; IPO pending)</strong>. The launch came weeks after 10x unveiled Sentira Spatial Analysis for users of 10x&#8217;s Atera <em class="zhvwWe" data-sfc-cp="" data-sfc-root="c" data-complete="true">in situ</em> spatial biology and transcriptomics platform.</p>
<p>Both applications apply Nvidia&#8217;s accelerated computing capabilities with the aim of speeding up widely used biological analysis methods; Sentira Spatial Analysis, for example, can reduce the analysis iteration cycle from hours on CPU alternatives to minutes. Underpinning that speed is rapids-singlecell, an open-source, GPU-accelerated Python library designed for large-scale single-cell omics analysis such as single-cell RNA sequencing. Rapids-singlecell was co-developed by Nvidia with scverse, an open-source, community-governed ecosystem of packages for single-cell and spatial omics.</p>
<aside class="my-8" style="clear:both" aria-label="Advertisement"><span id='malgam_render_6' data-render-ad='6'></span></aside>
<p><strong>&#8220;Incredibly powerful company&#8221;</strong></p>
<p>&#8220;Nvidia is an incredibly powerful company, and it&#8217;s not just one person who made it so,&#8221; Serge Saxonov, PhD, 10x&#8217;s co-founder and CEO, told <em>GEN</em> when asked whether recent Nvidia news including Huang&#8217;s resignation would cause 10x to review the partnership. &#8220;We&#8217;ve had an incredible relationship with the people over there. They&#8217;ve done incredible work in this collaboration.&#8221;</p>
<p>Over the past five years, Nvidia has initiated a variety of partnerships with tools developers, drug developers, and others within the life sciences. During the J.P. Morgan Healthcare Conference in January, Nvidia <a href="https://www.genengnews.com/topics/artificial-intelligence/jpm-nvidia-launches-ai-collaborations-with-eli-lilly-thermo-fisher/">launched a pair of collaborations with life-sci giants</a>: The company joined <strong>Eli Lilly (NYSE: LLY)</strong> in committing $1 billion over five years to create a “Co-Innovation AI Lab” designed to address key challenges in AI drug discovery. Nvidia also announced plans to integrate its AI technology into the lab instruments of <strong>Thermo Fisher Scientific (NYSE: TMO)</strong> through a collaboration intended to develop intelligent and increasingly autonomous laboratories.</p>
<p>Through a spokesperson, Thermo Fisher confirmed receipt of <em>GEN&#8217;s</em> query but offered no comment.</p>
<p>Also on the tools side, <strong>Danaher (NYSE: DHR)</strong> <a href="https://www.genengnews.com/topics/artificial-intelligence/danaher-nvidia-combine-lab-instrumentation-and-ai-to-advance-autonomous-science/">agreed to partner with Nvidia last month</a>. Danaher agreed to combine its scientific instrumentation, automation technologies, laboratory workflow software, and domain expertise with Nvidia’s accelerated computing and AI technologies.</p>
<p>Nvidia in recent years has also partnered with the Novo Nordisk Foundation, the nonprofit majority owner of Lilly&#8217;s arch-rival in obesity and diabetes drug development <strong>Novo Nordisk (Nasdaq Copenhagen: NOVO-B; NYSE: NVO). </strong> The foundation agreed in June 2025 to house an Nvidia supercomputer at the Danish Centre for AI Innovation, which last month announced it had invested in 32 NVIDIA DGX Rubin NVL8 systems, giving Denmark access to the latest generation of AI infrastructure.</p>
<p>Earlier, Nvidia partnered with British-based pharma giants <strong>AstraZeneca (London, Nasdaq Stockholm, and NYSE: AZN)</strong> and <strong>GlaxoSmithKline (London: GSK)</strong> to <a href="https://www.genengnews.com/topics/nvidia-powers-up-in-drug-discovery/" target="_blank" rel="noopener">build the U.K.’s most powerful supercomputer, Cambridge-1</a>, in 2020 through a partnership that also included the kingdom’s National Health Service (NHS).</p>
<p>Spokespeople for Lilly, AstraZeneca, and GSK at deadline had not responded to <em>GEN</em> queries about whether they would review their partnerships with Nvidia. Novo Nordisk referred <em>GEN</em> to the Danish Centre for AI Innovation, which at deadline had not responded either.</p>
<p>“Nvidia’s strength has always come from its people, and together with our leadership team, I am committed to building on the extraordinary foundation Jensen created over the last 33 years,” Kress said in a <a href="https://nvidianews.nvidia.com/news/nvidia-announces-ceo-transition">statement</a>. “We will continue advancing the work that has made Nvidia a leader in accelerated computing and AI, and execute on the opportunities ahead. Our focus remains on serving our customers, partners, developers and shareholders.”</p>
<h2><strong>PepGen nearly doubles on record-setting data</strong></h2>
<p><strong>PepGen (Nasdaq: PEPG)</strong> <span style="color: #000000;">nearly doubled </span>its stock price this past week after announcing dazzling mid-stage clinical results for its lead pipeline candidate PGN-EDODM1 that included the highest level of splicing correction ever reported in a multiple dose trial in patients with myotonic dystrophy type 1 (DM1).</p>
<aside class="my-8" style="clear:both" aria-label="Advertisement"><span id='malgam_render_7' data-render-ad='7'></span></aside>
<p>PepGen shares <span style="color: #008000;"><strong>rocketed 82%</strong></span> from $2.39 on Tuesday, when it announced its record-setting data, to $4.36 at Friday’s closing bell. The stock surge began when PGN-EDODM1, an enhanced delivery oligonucleotide (EDO) designed to address the underlying molecular mechanism of DM1, aced the Phase II FREEDOM2-DM1 trial (<a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fcts.businesswire.com%2Fct%2FCT%3Fid%3Dsmartlink%26url%3Dhttps%253A%252F%252Fclinicaltrials.gov%252Fstudy%252FNCT06667453%26esheet%3D54638669%26newsitemid%3D20261110113813%26lan%3Den-US%26anchor%3DNCT06667453%26index%3D2%26md5%3D5a92794d5b85f74e98acc93436221eb2&amp;data=05%7C02%7Calex.philippidis%40sagepub.com%7Ccb531c62777e4cc9439808df4036ce7c%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639300276903378491%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=R4jhElEbO8HDvsmXhtBQ34iSQ8Wb3z%2BqB4o5dxECqvI%3D&amp;reserved=0">NCT06667453</a>). PGN-EDODM1 attained a record-breaking 46.5% mean splicing correction in muscle, with four of six participants showing more than 50% splicing correction and all but one of the six, more than 20% splicing correction as measured by the 22-gene panel at Week 13.</p>
<p>In contrast, a pooled group of four participants receiving placebo (combined from Cohorts 1 and 2) showed a mean splicing correction of just 6.8% was 6.8% at Week 13.</p>
<p>Participants also showed sustained improvements in the video Hand Opening Time (vHOT), hand grip strength, 10-Meter Walk/Run Test (10MWRT), and Timed Up and Go (TUG) functional assessments—data that PepGen said offered compelling evidence of PGN-EDODM1’s potential to address multiple clinical manifestations of DM1 and supporting continued development.</p>
<p>“Our ambition is to fundamentally change how DM1 is treated through greater targeting of the underlying molecular mechanism of the disease,” James McArthur, PhD, PepGen’s president and CEO, said in a statement. “The 10 mg/kg results mark an important milestone in that pursuit, with robust splicing correction accompanied by encouraging improvements across multiple measures of muscle function.”</p>
<p>McArthur said the data strengthened PepGen’s confidence not only in PGN-EDODM1’s potential, but in the company’s broader development strategy.</p>
<p>“With our 12.5 mg/kg cohort fully enrolled and the ongoing FREEDOM-OLE study exceeding 135 doses administered, we believe we are well positioned to continue building the evidence needed to advance toward pivotal studies,” the CEO added.</p>
<p>PepGen quickly sought to cash in on its clinical triumph by launching a $125 million public offering of its common stock—though some investors could instead opt for pre-funded warrants to purchase shares of the stock. Net proceeds from the offering are intended, PepGen said, to fund ongoing clinical development of PGN-EDODM1, as well as provide working capital and address other general corporate purposes.</p>
<p>PepGen also granted the underwriters of its offering a 30-day option to purchase up to an additional $18.75 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. Leerink Partners, Stifel, and Guggenheim Securities acted as joint bookrunning managers for the proposed offering.</p>
<p><strong>&#8220;New bar in DM1&#8221;</strong></p>
<p>PepGen’s clinical success quickly won over analysts and investors.</p>
<p>“PEPG’s best-in-disease splicing and vHOT with favorable (renal) safety at 10[mg/kg] sets the new bar in DM1,” declared Kostas Biliouris, PhD, a managing director on the biotechnology research team of Oppenheimer.</p>
<p>Similarly, Debjit Chattopadhyay, PhD, a senior managing director and equity research analyst covering the biotechnology sector at Guggenheim Securities—one of the joint bookrunning managers for the $125 million public offering—hailed PepGen’s results as “potentially the new benchmark for splicing,” according to several published reports. Chattopadhyay contrasted PepGen’s 49% mean correction with the <a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.dyne-tx.com%2Fwp-content%2Fuploads%2FLilleker_2025_MDA_ACHIEVE_Poster.pdf&amp;data=05%7C02%7Calex.philippidis%40sagepub.com%7Ccb531c62777e4cc9439808df4036ce7c%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639300276903390053%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=NxeNPbdQGBLGYN4KvuC6p1jaL7W7C60BWHbr7UtmPd8%3D&amp;reserved=0">25% mean correction at three months</a> reported last year by Dyne Therapeutics (Nasdaq:DYN) from its Phase I/II ACHIEVE trial (<a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05481879&amp;data=05%7C02%7Calex.philippidis%40sagepub.com%7Ccb531c62777e4cc9439808df4036ce7c%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639300276903400969%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=FLMs4PEuSozS%2FHMrQAKPpGb27YGnFuwqTWRvDGgkjzM%3D&amp;reserved=0">NCT05481879</a>) evaluating a 6.8 mg/kg every eight weeks dose of DM1 candidate DYNE-101.</p>
<p>Tazeen Ahmad, a senior research analyst covering large-cap and small-cap biotechnology companies with BofA Securities, upgraded PepGen shares from “Underperform” to “Neutral,” and raised her firm’s 12-month price target on the company’s shares 140%, from $2.50 to $6.</p>
<p>Investors responded with a buying surge that sent PepGen stock nearly doubling on November 10, <span style="color: #008000;"><strong>rocketing nearly 93%</strong></span> from $2.39 to $4.61. Shares <span style="color: #008000;"><strong>soared another 14%</strong></span> Wednesday, reaching $5.26 before <span style="color: #ff0000;"><strong>dropping 4%</strong></span> to $5.04 Thursday and <span style="color: #ff0000;"><strong>skidding another 13.5%</strong></span> Friday.</p>
<h2>Leaders and laggards</h2>
<ul>
<li><strong>Capricor Therapeutics (Nasdaq: CAPR)</strong> shares <span style="color: #008000;"><strong>jumped 26.5%</strong></span> from $8.87 to $11.22 Wednesday after JonesTrading upgraded its rating of the company’s stock from “Hold” to “Buy” with a $25 price target. JonesTrading cited the upcoming Prescription Drug User Fee Act (PDUFA) target action date of November 22 on the company’s re-submitted Biologics License Application (BLA) for its lead cell therapy candidate deramiocel in Duchenne muscular dystrophy (DMD). In August, Capricor proposed narrowing its indication to treating upper limb impairment in DMD patients &gt;9 years old, the population studied in its HOPE-3 trial (<a href="https://clinicaltrials.gov/study/NCT05126758">NCT05126758</a>) and the focus of its primary endpoint. The company also submitted two-year open-label extension data and additional robustness analyses from HOPE-3, and an integrated summary of efficacy across HOPE-3 and the earlier Phase II HOPE-2 trial (<a href="https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT03406780&amp;data=05%7C02%7Calex.philippidis%40sagepub.com%7C4571c158c0f349617bec08deee5ea16e%7C866b3abd7515461abdb412b4a1857f04%7C0%7C0%7C639210287674957401%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=jfCAmFpi0Jb9AWfISbsBGxnx0L0%2F7atGyRuFk8m9bMw%3D&amp;reserved=0">NCT03406780</a>). The FDA classified the August submission as a major amendment, extending the review by three months from the original August 22 date.</li>
<li><strong>Oragenics (NYSE American: OGEN)</strong> shares <span style="color: #ff0000;"><strong>plummeted nearly 43%</strong></span> from 35 cents to 20 cents Friday, after the developer of intranasal brain-targeted therapeutics announced third quarter results showing a net quarterly loss of $2.603 million, and a nine-month net loss of $7.333 million. The stock plunge occurred despite positive news: The NYSE Regulation rules enforcement arm had accepted its plan to regain compliance with NYSE American listing standards and granted an extension through February 25, 2028 to do so. “We believe this approval allows us to maintain our NYSE American listing while we continue to pursue our strategic priorities, capital raising initiatives, and investment strategies designed to enhance long-term value for our shareholders,” CEO Janet Huffman stated. Oragenics lost compliance due to a low stockholders’ equity of $3.7 million as of June 30, plus losses from continuing operations and/or net losses in its five most recent fiscal years ended December 31, 2025.</li>
</ul>
<p>The post <a href="https://www.genengnews.com/topics/artificial-intelligence/stockwatch-amid-nvidia-turmoil-what-happens-to-its-life-sciences-collaborations/">StockWatch: Amid Nvidia Turmoil, What Happens to Its Life Sciences Collaborations?</a> appeared first on <a href="https://www.genengnews.com">GEN - Genetic Engineering and Biotechnology News</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>DCIS Cell Atlas Reveals Clues to Invasive Breast Cancer Progression</title>
		<link>https://www.genengnews.com/topics/cancer/dcis-cell-atlas-reveals-clues-to-invasive-breast-cancer-progression/</link>
		
		<dc:creator><![CDATA[Sophia Ktori]]></dc:creator>
		<pubDate>Fri, 13 Nov 2026 22:04:09 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Drug Discovery]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Topics]]></category>
		<category><![CDATA[Translational Medicine]]></category>
		<guid isPermaLink="false">https://www.genengnews.com/?p=340597</guid>

					<description><![CDATA[<p>Researchers created a detailed map of the tumor microenvironment surrounding estrogen receptor-positive ductal carcinoma <i>in situ</i>, which may help better predict progression to invasive breast cancer and inform on future therapeutic strategies. </p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/dcis-cell-atlas-reveals-clues-to-invasive-breast-cancer-progression/">DCIS Cell Atlas Reveals Clues to Invasive Breast Cancer Progression</a> appeared first on <a href="https://www.genengnews.com">GEN - Genetic Engineering and Biotechnology News</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Researchers at The University of Texas MD Anderson Cancer Center have created what they say is one of the most detailed maps to date of the tumor microenvironment (TME) surrounding estrogen receptor-positive (ER+) ductal carcinoma <em>in situ</em> (DCIS), the most common form of preinvasive—stage 0—breast cancer. The atlas was created by analyzing samples from normal breast tissue, DCIS and invasive breast cancers.</p>
<p>The study findings may help to explain why some lesions progress to invasive breast cancer and others do not and inform strategies for improving patient risk prediction and developing better targeted approaches for those at higher risk of invasive disease.</p>
<p>“DCIS is considered a snapshot before breast cancer becomes invasive, but not all DCIS cases progress to invasive disease, and the biology surrounding these lesions has been challenging to examine,” said research co-lead Nicholas Navin, PhD, chair of Systems Biology. “This atlas reveals the surrounding cells and structures that may help disease become invasive. In the future, these findings may allow clinicians to better identify and treat patients with DCIS who are at higher risk of invasive progression while also avoiding unnecessary treatments for those at low risk.”</p>
<p>Navin, together with research co-lead Savitri Krishnamurthy, MD, professor of Anatomical Pathology, as well as co-first authors Siyuan He, PhD, and Aatish Thennavan, PhD, postdoctoral fellows of Systems Biology, and colleagues, reported on their findings in <em>Science,</em> in a paper titled “<a href="http://dx.doi.org/10.1126/science.aef4622" target="_blank" rel="noopener">A cellular atlas of the preinvasive breast cancer microenvironment</a>.” In their report the team stated that their data “… greatly improve our fundamental understanding of the DCIS microenvironment and the progression of invasive disease.”</p>
<p>DCIS occurs when abnormal cells grow inside the breast milk ducts but have not yet spread into surrounding tissue, and is considered to be a precursor to the most common type of breast cancer. “Ductal carcinoma <em>in situ</em> (DCIS) is precursor of invasive ductal carcinoma (IDC), in which the preinvasive cells are confined within the basement membrane of breast ductal-lobular structures,” the authors wrote.</p>
<p>Mammograms and other breast examinations have increased the detection of DCIS cases, but many of these lesions never progress to invasive disease, making it challenging to determine which patients actually need more aggressive treatment. “Over the last three decades, routine breast mammography screening has led to overdiagnosis of DCIS that now represents up to 25% of all diagnosed breast cancer cases,” the team continued. “If left untreated, only 10-30% of women with DCIS will progress to invasive disease.”</p>
<p>While genetic changes in DCIS have been well-studied, little is known about its tumor microenvironment—the community of immune cells, blood vessels and tissue cells that surround and interact with the cancer cells. The researchers set out to generate a comprehensive cell atlas for DCIS. Using advanced single-cell and spatial profiling technologies, they mapped more than 850,000 cells from samples of normal breast tissue, DCIS and invasive breast cancer. They identified extensive changes in cancer cells and the surrounding microenvironment as disease progressed. “We analyzed 854,911 cells from 159 patients by single cell RNA sequencing and 39 samples by spatial transcriptomics, which identified nine cell types and 60 cell states,” they reported.</p>
<p>The resulting detailed atlas suggests that important biological features associated with invasive breast cancer begin to emerge earlier than previously known. The study also uncovered previously unknown “cancer stromal loops,” ring-like structures made of supportive tissue and vascular cells that surround DCIS lesions, which create conditions that support tumor growth. “Our data reports on remodeling of specific immune, stromal cell types and myoepithelial cells in the DCIS TME, along with changes in cancer cell metaprograms that form cellular ecosystems and spatial niches to support the growth and progression of DCIS,” they wrote in summary.</p>
<p>Additional research is needed to validate these findings and evaluate their potential use in future diagnostic tools and prevention or treatment strategies. The findings could one day help doctors predict which patients need aggressive treatment and which patients may safely avoid it.  The team said researchers will continue studying the cellular features identified in the atlas to determine whether they can predict which DCIS lesions are most likely to become invasive, to help better determine the best strategies for individual patients.</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/dcis-cell-atlas-reveals-clues-to-invasive-breast-cancer-progression/">DCIS Cell Atlas Reveals Clues to Invasive Breast Cancer Progression</a> appeared first on <a href="https://www.genengnews.com">GEN - Genetic Engineering and Biotechnology News</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>How Vancomycin-Resistant Enterococcus Evolved in a Danish Hospital</title>
		<link>https://www.genengnews.com/topics/infectious-diseases/how-vancomycin-resistant-enterococcus-evolved-in-a-danish-hospital/</link>
		
		<dc:creator><![CDATA[Julianna LeMieux, PhD]]></dc:creator>
		<pubDate>Fri, 13 Nov 2026 20:02:36 +0000</pubDate>
				<category><![CDATA[Infectious Diseases]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[OMICs]]></category>
		<category><![CDATA[Topics]]></category>
		<guid isPermaLink="false">https://www.genengnews.com/?p=340624</guid>

					<description><![CDATA[<p>A genomic study reveals how genetic mutations, recombination, and resistance-carrying plasmids shaped the evolution, diversification, and decline of vancomycin-resistant <i>Enterococcus faecium</i> in Danish hospitals between 2012 and 2020.</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/how-vancomycin-resistant-enterococcus-evolved-in-a-danish-hospital/">How Vancomycin-Resistant &lt;i&gt;Enterococcus&lt;/i&gt; Evolved in a Danish Hospital</a> appeared first on <a href="https://www.genengnews.com">GEN - Genetic Engineering and Biotechnology News</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p style="font-weight: 400;">Vancomycin-resistant <em>Enterococcus faecium</em> is listed by the World Health Organization—in its 2024 Bacterial Priority Pathogens List—as one of the highest-priority bacteria.</p>
<p style="font-weight: 400;">In a new study published in <em>Genome Medicine</em>, researchers from Instituto de Tecnologia Química e Biológica António Xavier from NOVA University of Lisbon (ITQB NOVA), in Portugal, investigated the genetic mechanisms behind the rise and fall of the dominant vancomycin-resistant <em>Enterococcus faecium</em> clone (VREfm ST80) from 2012 to 2020 in Danish hospitals. The team assembled and performed whole-genome sequencing and phylogenomic analysis of 334 ST80 isolates collected from colonization (83%) and infection (17%) cases across nine hospitals in the region between 2012 and 2020.</p>
<p style="font-weight: 400;">The results identified two major clusters (Clusters 1 and 2) and nine sub-clusters (1.A–G and 2.H–I). Sub-cluster-1.A (169/334) was the dominant lineage, accounting for 72% of isolates from 2012–2015. The isolates from 2016–2020 “were distributed across all sub-clusters, indicating increasing diversification over time.”</p>
<p style="font-weight: 400;">Genetic variation, the authors write, was “driven by accumulation of mutations, recombination and gain/loss of accessory genes and plasmids.” Eight recombination hotspots were identified in core genes involved in cell wall synthesis, phosphotransferase systems, amino-acid biosynthesis, and several transporters.</p>
<p style="font-weight: 400;">This work is published in <em>Genome Medicine</em> in the paper, “<a href="https://link.springer.com/article/10.1186/s13073-026-01747-2" target="_blank" rel="noopener">Recombination and accessory genome turnover shaped the rise and decline of <em>vanA Enterococcus faecium</em> ST80 in Denmark.</a>”</p>
<p style="font-weight: 400;">The team also found that this bacterial clone carried a mosaic phage-like plasmid element that made it resistant to several antibiotics at once. The element harbored the <em>vanA</em> operon with <em>ermB, aadE</em>, and <em>aph(3’)-IIIa</em> suggesting “a unique mechanism for co-mobilization of antimicrobial resistance via transduction or conjugation.”</p>
<p style="font-weight: 400;">“Using any one of those antibiotics can select for bacteria carrying the whole package, including vancomycin resistance,” explains Maria Miragaia, PhD, leader of the Bacterial Evolution and Molecular Epidemiology lab at ITQB NOVA. “This means that simply reducing vancomycin use may not be enough to reduce vancomycin-resistant bacteria if other linked antibiotics are still being used,” she adds.</p>
<p style="font-weight: 400;">The study suggests that targeting the strategies that helped the clone persist—forming biofilms, altering its outer surface, and using alternative sugars in the gut—could help to clear these resistant bacteria from the gut and reduce their spread in hospitals.</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/how-vancomycin-resistant-enterococcus-evolved-in-a-danish-hospital/">How Vancomycin-Resistant &lt;i&gt;Enterococcus&lt;/i&gt; Evolved in a Danish Hospital</a> appeared first on <a href="https://www.genengnews.com">GEN - Genetic Engineering and Biotechnology News</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Downstream Processing: Purifying Complex Antibody Therapeutics When Target Molecules Misbehave</title>
		<link>https://www.genengnews.com/multimedia/webinars/downstream-processing-purifying-complex-antibody-therapeutics-when-target-molecules-misbehave/</link>
		
		<dc:creator><![CDATA[Kathy Vuksanaj]]></dc:creator>
		<pubDate>Fri, 13 Nov 2026 15:39:32 +0000</pubDate>
				<category><![CDATA[Bioprocessing]]></category>
		<category><![CDATA[Multimedia]]></category>
		<category><![CDATA[Translational Medicine]]></category>
		<category><![CDATA[Upcoming]]></category>
		<category><![CDATA[Webinars]]></category>
		<guid isPermaLink="false">https://www.genengnews.com/?p=340609</guid>

					<description><![CDATA[<p>In this <i>GEN</i> webinar, downstream process development and scale up manufacturing specialists will discuss practical strategies for building robust purification processes when the target molecule misbehaves.</p>
<p>The post <a href="https://www.genengnews.com/multimedia/webinars/downstream-processing-purifying-complex-antibody-therapeutics-when-target-molecules-misbehave/">Downstream Processing: Purifying Complex Antibody Therapeutics When Target Molecules Misbehave</a> appeared first on <a href="https://www.genengnews.com">GEN - Genetic Engineering and Biotechnology News</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow"></div>
</div>


<p><button class="wp-block-malblocks-scroll-button scroll-button theme-bg">Register Now</button></p>

<h3 class="w-full text-left">
    <strong>
         Panelists    </strong>
</h3>
<div class="flex flex-row m-0-auto items-stretch justify-center flex-wrap mb-4">
    
<div id="presenter-card-0"
    class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div id="presenter-content-0"
            class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/11/Scherr-headshot-e1794584066338.png" class="h-full w-full object-cover"
                        alt="Image of David Scherr, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">David Scherr, PhD</h2>
                <h3 class="mt-0 !text-[15px] !leading-[21px]"
                    style="color: #444444">Sr. Scientist<br>Bioprocess Technologies &#038; Engineering<br>Biopharmaceutical Development<br>AstraZeneca</h3>
            </div>
            <button
                type="button"
                onclick="presenter_modal_0.showModal()"
                class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog id="presenter_modal_0" class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button
                onclick="presenter_modal_0.close()"
                class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg"
                    alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/11/Scherr-headshot-e1794584066338.png"
                            alt="Image of David Scherr, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">David Scherr, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"
                        style="color: #444444"><p>David Scherr, PhD, is a senior scientist at AstraZeneca focusing on downstream process development for the Integrated Dynamic Bioprocessing (IDB) platform. He joined AstraZeneca in 2023 and has been a part of CMC teams for GMP implementation of continuous antibody purification. David has also led efforts to implement high-throughput process development and AI-first ways of working. David earned his BS in biochemistry and chemistry from the University of Miami followed by a PhD in biological systems engineering at Virginia Tech.</p>
                    </p>
                    <div class="dui-modal-action">
                    <form method="dialog" class="bg-white">
                        <!-- if there is a button in form, it will close the modal -->
                        <button
                            type="button"
                            onclick="presenter_modal_0.close()"
                            class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    </form>
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div id="presenter-card-1"
    class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div id="presenter-content-1"
            class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/11/Kante-headshot-e1794584145723.jpg" class="h-full w-full object-cover"
                        alt="Image of Anupama Kante, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Anupama Kante, PhD</h2>
                <h3 class="mt-0 !text-[15px] !leading-[21px]"
                    style="color: #444444">Scientist<br>Avid Bioservices</h3>
            </div>
            <button
                type="button"
                onclick="presenter_modal_1.showModal()"
                class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog id="presenter_modal_1" class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button
                onclick="presenter_modal_1.close()"
                class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg"
                    alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/11/Kante-headshot-e1794584145723.jpg"
                            alt="Image of Anupama Kante, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Anupama Kante, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"
                        style="color: #444444"><p>Anupama Kante, PhD, is a scientist in downstream process development at Avid Bioservices specializing in biologics purification, formulation development, and analytical characterization. She has extensive experience advancing monoclonal antibodies and complex biologics from early development through process optimization. Anupama is passionate about building scientific capabilities, driving innovation, and translating technical insights into practical solutions.</p>
                    </p>
                    <div class="dui-modal-action">
                    <form method="dialog" class="bg-white">
                        <!-- if there is a button in form, it will close the modal -->
                        <button
                            type="button"
                            onclick="presenter_modal_1.close()"
                            class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    </form>
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog>
<div id="presenter-card-2"
    class="border-none min-h-48 w-full md:w-1/2 grow lg:w-1/3 xl:w-1/4  xl:max-w-1/4 md:max-w-1/2 lg:max-w-1/3">
    <div class="items-center w-full flex flex-col gap-2 align-center">
        <div id="presenter-content-2"
            class="p-6 flex flex-col bg-white rounded-md text-center">
            <div class="flex flex-col items-center grow gap-2">
                <div class="!max-w-[150px] !mb-6 !overflow-hidden rounded-full aspect-square">
                    <img decoding="async" src="https://www.genengnews.com/wp-content/uploads/2026/11/Ruesing-headshot-e1794584239214.jpg" class="h-full w-full object-cover"
                        alt="Image of Sam Ruesing, PhD">
                </div>
                <h2 class="!text-[16px] !leading-[24px] !font-palatino !font-bold mt-0 mb-0">Sam Ruesing, PhD</h2>
                <h3 class="mt-0 !text-[15px] !leading-[21px]"
                    style="color: #444444">Sr. Staff Scientist<br>Thermo Fisher Scientific</h3>
            </div>
            <button
                type="button"
                onclick="presenter_modal_2.showModal()"
                class="!w-auto hover:!bg-gray-100 !py-[16px] !px-[18px] self-center !mt-1 !text-xl shadow-none !text-gen-red dui-btn rounded-none border-1 !bg-white text-center !border-gen-red hover:!border-borderDark focus:!border-borderDark font-roboto! font-bold">
                View Bio
            </button>
        </div>
    </div>
</div>
<dialog id="presenter_modal_2" class="dui-modal">
    <div class="dui-modal-box bg-white p-0 rounded-none min-w-1/2 w-full max-w-full  sm:max-w-5/6 lg:max-w-[1040px]">
        <div class="!pl-5 !pr-3 flex flex-row space-between w-full items-center !py-2">
            <h3 class="font-normal w-full !text-gray-600 !font-roboto mb-0 py-2 !text-[20px]">Panelist</h3>
            <button
                onclick="presenter_modal_2.close()"
                class="dui-btn !highlight-none hover:!bg-white shadow-none !bg-white border-none">
                <img decoding="async" class="text-gray-200 mb-0" src="/wp-content/themes/genengnews-nonnewspaper/assets/svg/icons8-close-18.svg"
                    alt="Close Button">
            </button>
        </div>
        <div class="w-full bg-gray-200 h-[1px]"></div>        <div class="p-4 flex flex-col justify-center">
            <div class="grid grid-cols-1 sm:grid-cols-[150px_1fr_1fr_1fr] mx-[7%] my-8">
                <div class="flex flex-row w-full justify-center">
                    <div class="col-span-1 !overflow-hidden !max-w-[150px]">
                        <img decoding="async" class="object-cover" src="https://www.genengnews.com/wp-content/uploads/2026/11/Ruesing-headshot-e1794584239214.jpg"
                            alt="Image of Sam Ruesing, PhD">
                    </div>
                </div>
                <div class="flex flex-col col-span-3 sm:!ml-12 biomodal">
                    <h2 class="!text-[20px] !mb-4 !font-palatino !font-bold mt-0 !text-center sm:!text-left">Sam Ruesing, PhD</h2>
                    <p class="!text-[15px] !leading-[24px] text-justify"
                        style="color: #444444"><p>Sam Ruesing, PhD, is a senior staff scientist in downstream process development at Thermo Fisher Scientific. He holds a bachelor’s degree in chemical engineering from the Missouri University of Science and Technology and PhD in biomedical engineering from Saint Louis University. Sam’s experience spans all aspects of downstream development, including early-phase development for first-in-human production, adapting processes to new facilities, and late-phase optimization and characterization in preparation for commercialization.</p>
                    </p>
                    <div class="dui-modal-action">
                    <form method="dialog" class="bg-white">
                        <!-- if there is a button in form, it will close the modal -->
                        <button
                            type="button"
                            onclick="presenter_modal_2.close()"
                            class="!w-auto shadow-none bottom-12 right-12 sm:static !text-xl !text-gen-red dui-btn rounded-none !bg-white border-1 text-center hover:!bg-gray-100 !border-gen-red hover:!border-borderDark focus:border-borderDark !py-[16px] !px-[18px] self-center mt-1 text-6 font-roboto! font-bold">
                            Close
                        </button>
                    </form>
                </div>
                </div>
                
            </div>
            <div class="w-full bg-gray-200 h-[1px]"></div>        </div>
    </div>

</dialog></div>



<div style="height:34px" aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-malblocks-webinars-info"><div><strong>Broadcast Date:</strong> <time>Tuesday, December 8, 2026</time><br/><ul style="list-style-type:none;padding-left:0"><li style="margin-bottom:0;margin-left:0"><strong>Time:</strong> <time datetime="2026-12-08T16:00:00.000Z">08:00 PST, 11:00 EST, 16:00 GMT</time></li></ul></div></p>


<div style="height:43px" aria-hidden="true" class="wp-block-spacer"></div>


<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow" style="flex-basis:100%">
<p class="wp-block-paragraph">As antibody-based therapeutics move beyond IgG monoclonal antibodies, downstream process development teams have to purify molecules that do not always fit established platform assumptions. Bispecifics, multispecifics, antibody fragments, Fc-fusion proteins, ADCs, and other engineered formats can introduce new challenges in assembly, stability, impurity profiles, and scalability. Separation of the target molecule from mispaired chains, homodimers, aggregates, fragments, free light chains, persistent host cell proteins, and format-specific product variants can fall outside the limits of standard Protein A, AEX, and CEX purification workflows. For many PD teams, the platform process remains the proper starting point, but the molecule does not always behave like the platform expects.</p>


<p class="wp-block-paragraph">In this <em>GEN</em> webinar, downstream process development and scale up manufacturing specialists will discuss practical strategies for building robust purification processes when the target molecule misbehaves. The discussion will explore how teams decide whether to stay with a platform, adapt it, or move to a more molecule-specific toolbox, how alternative affinity approaches can help when Protein A lacks selectivity or is not applicable, and how polishing strategies with IEX, HIC, and mixed-mode chromatography can be used to address difficult product- and process-related impurities. The panel will also discuss how to balance speed, yield, purity, cost of goods, analytical burden, scalability, and regulatory expectations from early development through tech transfer and manufacturing of standard mAbs and beyond.</p>


<div style="height:40px" aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><em>A live Q&amp;A session will follow the presentation offering you a chance to pose questions to our expert panelists.</em></p>


<div style="height:30px" aria-hidden="true" class="wp-block-spacer"></div>


<p class="wp-block-paragraph"><strong>Produced with support from:</strong></p>


<figure class="wp-block-image alignleft size-medium"><a href="https://www.thermofisher.com/" target="_blank" rel=" noopener"><img decoding="async" width="300" height="138" src="https://www.genengnews.com/wp-content/uploads/2023/03/ThermoFisher_logo-300x138.png" alt="Thermo Fisher logo" class="wp-image-221790" srcset="https://www.genengnews.com/wp-content/uploads/2023/03/ThermoFisher_logo-300x138.png 300w, https://www.genengnews.com/wp-content/uploads/2023/03/ThermoFisher_logo.png 558w" sizes="(max-width: 300px) 100vw, 300px" /></a></figure>
</div>
</div>

<p>The post <a href="https://www.genengnews.com/multimedia/webinars/downstream-processing-purifying-complex-antibody-therapeutics-when-target-molecules-misbehave/">Downstream Processing: Purifying Complex Antibody Therapeutics When Target Molecules Misbehave</a> appeared first on <a href="https://www.genengnews.com">GEN - Genetic Engineering and Biotechnology News</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Reference Genomes of Malaria-Causing Plasmodium Parasites Completed</title>
		<link>https://www.genengnews.com/topics/infectious-diseases/reference-genomes-of-malaria-causing-plasmodium-parasites-completed/</link>
		
		<dc:creator><![CDATA[Savannah Wiegel]]></dc:creator>
		<pubDate>Thu, 12 Nov 2026 23:44:45 +0000</pubDate>
				<category><![CDATA[Infectious Diseases]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Topics]]></category>
		<guid isPermaLink="false">https://www.genengnews.com/?p=340577</guid>

					<description><![CDATA[<p>Using DNA sequenced from patient blood samples, researchers assembled complete reference genomes of neglected malaria parasites, uncovering genetic regions potentially involved in immune evasion and providing new tools for disease surveillance.</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/reference-genomes-of-malaria-causing-plasmodium-parasites-completed/">Reference Genomes of Malaria-Causing &lt;i&gt;Plasmodium&lt;/i&gt; Parasites Completed</a> appeared first on <a href="https://www.genengnews.com">GEN - Genetic Engineering and Biotechnology News</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Researchers have generated the most complete chromosome-level reference genomes to date for two understudied malaria parasites, uncovering previously inaccessible genetic regions that could help explain how the pathogens evade immune defenses and persist in human hosts.</p>
<p>The study, titled “<a href="https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1014754" target="_blank" rel="noopener">High quality chromosomal genome assemblies of three human <em>Plasmodium </em>species directly from natural infection</a>,” and published in <em>PLOS Pathogens, </em>describes a method for assembling chromosome-level genomes directly from patient blood samples without laboratory culturing. The findings could improve parasite identification, genomic surveillance, and efforts to monitor emerging drug resistance.</p>
<p>Although <em>Plasmodium falciparum </em>is responsible for most malaria-related deaths, other species, including <em>P. ovale </em>and <em>P. malariae</em>, also contribute to the global disease burden. These parasites can cause chronic infections but remain comparatively poorly understood, partly because researchers lack reliable methods for growing them continuously in laboratory cultures.</p>
<p>To address these limitations, scientists at the Wellcome Sanger Institute and the Parasites and Microbes Research and Training Center in Mali collected blood samples from patients with naturally acquired malaria infections in Faladie, Mali.</p>
<p>The team enriched parasite DNA by removing human white blood cells and uninfected red blood cells before applying PacBio Ultra-Low-Input HiFi long-read sequencing. They combined this approach with Hi-C, a technique that captures interactions between DNA regions to reconstruct chromosome organization.</p>
<p>The researchers ultimately assembled parasite genomes from eight participants, producing high-quality references for <em>P. ovale wallikeri, P. malariae, </em>and <em>P. falciparum.</em></p>
<p>Unlike earlier fragmented references, the new assemblies resolved previously inaccessible regions near chromosome ends, known as subtelomeric regions. These areas contain repetitive DNA and expanded gene families associated with interactions between parasites and their human hosts, enhancing “understanding of parasite persistence, transmission, immune evasion, and comparative evolutionary studies.”</p>
<p>Notably, the researchers identified more than 2,000 genes belonging to the <em>PIR </em>gene family in <em>P. ovale wallkeri, </em>accounting for approximately one-quarter of its genome.</p>
<p>Comparisons among parasites collected from the same geographic region also revealed extensive genetic rearrangements near chromosome ends, highlighting mechanisms that may contribute to antigenic variation and immune invasion.</p>
<p>“Uncovering these full genomes revealed the extent of expansions of gene families sitting at the ends of chromosomes, which regularly shuffle genetic material to adapt and evade the human immune system,” said first author Sunil Dogga, PhD, formerly of the Wellcome Sanger Institute and now at the Swiss Tropical and Public Health Institute.</p>
<p>The findings are particularly relevant as malaria elimination efforts increasingly confront infections caused by non-<em>falciparum </em>species, which can be difficult to diagnose and may persist even where <em>P. falciparum </em>transmission declines.</p>
<p>Beyond improving understanding of parasite biology, the genomic resources could support development of more accurate molecular diagnostics, identification of potential therapeutic targets, and studies investigating how parasite populations respond to treatment and control measures.</p>
<p>“Establishing gold-standard reference genomes for these neglected parasites fills a critical knowledge gap in global malaria research,” said senior author Mara Lawniczak, PhD, group leader at the Wellcome Sanger Institute.</p>
<p>The researchers emphasized that incorporating these overlooked species into genomic surveillance will be important for developing more comprehensive malaria elimination strategies. The authors wrote, “This work provides a critical foundation for including these neglected species in global malaria elimination efforts.”</p>
<p>&nbsp;</p>
<p>The post <a href="https://www.genengnews.com/topics/infectious-diseases/reference-genomes-of-malaria-causing-plasmodium-parasites-completed/">Reference Genomes of Malaria-Causing &lt;i&gt;Plasmodium&lt;/i&gt; Parasites Completed</a> appeared first on <a href="https://www.genengnews.com">GEN - Genetic Engineering and Biotechnology News</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>High Frequency of Drug-Impacting Gene Variants Found in All of Us Cohort</title>
		<link>https://www.genengnews.com/topics/omics/high-frequency-of-drug-impacting-gene-variants-found-in-all-of-us-cohort/</link>
		
		<dc:creator><![CDATA[Sophia Ktori]]></dc:creator>
		<pubDate>Thu, 12 Nov 2026 20:17:04 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<category><![CDATA[OMICs]]></category>
		<category><![CDATA[Topics]]></category>
		<category><![CDATA[Translational Medicine]]></category>
		<guid isPermaLink="false">https://www.genengnews.com/?p=340571</guid>

					<description><![CDATA[<p>A study finds that everyone in a diverse, nearly 100,000-person sample carried at least one genetic variant that affects how their body processes medications, and a quarter of those people had been prescribed a medication that is known to be impacted by the variant they carried.</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/high-frequency-of-drug-impacting-gene-variants-found-in-all-of-us-cohort/">High Frequency of Drug-Impacting Gene Variants Found in &lt;i&gt;All of Us&lt;/i&gt; Cohort</a> appeared first on <a href="https://www.genengnews.com">GEN - Genetic Engineering and Biotechnology News</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>A study headed by researchers at the University of Pittsburgh has found that everyone in a diverse, nearly 100,000-person sample from the National Institutes of Health’s <em>All of Us</em> Research Program (All of Us) carried at least one genetic variant that affects how their body processes medications. The results also showed that a quarter of those people had been prescribed a drug that is known to be impacted by the variant they carried.</p>
<p>The researchers say the discovery highlights the value of genetic testing for some medications and that electronic health record alerts could be helpful when a clinician prescribes one of these drugs. Such an alert would allow the clinician to consider prescribing an alternate medication or adjusting the dosage, if appropriate.</p>
<p>“Many people have experience with taking a medication that is not working well for them or that has a side effect,” said Philip E. Empey, PharmD, PhD, associate professor in Pitt’s School of Pharmacy and associate director for pharmacogenomics at the Institute for Precision Medicine at Pitt and UPMC. “While many things impact how a patient responds to medication, our research tells us that genetics could be [a] factor for a large proportion of patients and it points to the value of precision medicine in prescribing.”</p>
<p>Empey is senior author of the researchers’ published paper in <em>Science Translational Medicine</em>, titled “<a href="http://dx.doi.org/10.1126/scitranslmed.adt8040" target="_blank" rel="noopener">Frequency of pharmacogenomic variation and medication exposures among <em>All of Us</em> Participants</a>.”</p>
<p>Pharmacogenomics (PGx) promises improved outcomes through individualized prescribing, the authors wrote in their paper. “PGx can impact drug effectiveness and toxicity. Many commonly prescribed medications have genotype-guided dosing or drug selection recommendations in their Food and Drug Administration (FDA) approved labeling or in guidelines developed by the Clinical Pharmacogenetics Implementation Consortium (CPIC).”</p>
<p>More than 300 medications have information on their labels about genetic variant interactions, where genetic testing may be of value to guide prescribing, Empey said. One example is a chemotherapy drug used for colon cancer that could have serious toxicity in up to 8% of patients who carry these genetic variants, so those patients are proactively tested before treatment. However, the authors noted, “Despite the strong evidence supporting the use of PGx data in clinical practice, broader implementation is limited in part by the relative paucity of data on the frequency of variants, alleles, and predicted phenotypes across diverse biogeographical groups.”</p>
<p>For their reported study the research team used data from the National Institutes of Health (NIH) <a href="https://www.nih.gov/allofus" target="_blank" rel="noopener"><em>All of Us</em> Research Program</a>, an initiative that aims to gather data from one million people across the U.S. to help better understand how lifestyle, environment, and genes influence health and disease. Pitt is a key partner in the program, launching All of Us Pennsylvania in 2018. “This study represents one of the largest and the most diverse PGx datasets with linked medication exposures events to date,” the team noted. “<em>All of Us</em> has particular value in identifying and understanding the frequency of both previously unknown and rare variants because of the size of the cohort, comprehensiveness in genotyping approach, and the genetic diversity.”</p>
<p>The team evaluated the frequency of 16 genetic variants known to impact the effectiveness or toxicity of various medications among nearly 100,000 <em>All of Us</em> participants. The results showed that everyone in the study was found to carry at least one such variant with a median of nine variants. “We found 100% of participants carried at least one known PGx variant and nearly all (99.49%) had a predicted phenotype for a gene which has a CPIC or FDA recommendation for a change in prescribing,” they stated. “Among nearly 100k participants in <em>All of Us</em> Research Program, pharmacogenomic variants and actionable results are common and the diversity of the cohort provided for identification of novel variants and population frequencies.”</p>
<p>By then matching the genetic data to the participants’ medical records, the research team also found that more than 24% of participants had been prescribed at least one medication known to interact with a variant they carried. “Clinical impact was high with 24.38% of participants having both an actionable phenotype for these pharmacogenes and a prior exposure to an impacted medication with pharmacogenomic prescribing guidance,” they wrote. The most common medications identified in the review were ondansetron (anti-nausea), ibuprofen (anti-inflammatory), omeprazole and pantoprazole (both treat acid reflux and heartburn), and atorvastatin (lowers cholesterol).</p>
<p>The team also identified over 17,000 novel variants and reported the frequency of known medication-linked genetic variants across multiple ancestry groups, including in populations where these frequencies were not previously estimated. “Importantly, we report thousands of novel variants as well as hundreds of alleles and predicted phenotypes that deviate from known frequencies and/or were previously unreported, especially within Americas and African ancestry groups.” they wrote in summary.</p>
<p>“The limited diversity of racial and ethnic groups in early studies is a challenge in genetic research and skews risk estimates,” Empey said. “That’s part of the beauty of the <em>All of Us</em> Research Program—it was intentionally designed to help close these gaps by including people from a wide range of age groups, backgrounds, and life experiences. It also underscores the value of having a large precision medicine dataset where whole genome testing data can be studied along with clinical data.”</p>
<p>Empey said it will be up to policy makers and health insurers to weigh the benefits of widespread genetic screening for variants that interact with medications against the cost, and that this is a very active area of research. He said it makes sense to screen patients with a panel test that can look for common variants that are known to affect many medications and have these results in their medical record, much like a test for kidney function. This approach is also being applied in situations where patients are on many medications at the same time or in patients starting certain medications known to be impacted by genetics, such as clopidogrel, a medication used after cardiac stenting.</p>
<p>People who have already undergone pharmacogenomic testing should be sure to share their results with their pharmacists and prescribers so that it is integrated with their electronic health record, said Empey, who is leading efforts at UPMC to make it easy for clinicians to see if a patient carries variants that may affect a medication that they’re prescribing and recommend changes when needed.</p>
<p>“Just like with any new technology, it comes down to responsible implementation,” Empey said. “Costs are coming down and the data is increasing, so it is important for patients and clinicians to be aware that the use of precision medicine in prescribing is becoming commonplace.”</p>
<p>The post <a href="https://www.genengnews.com/topics/omics/high-frequency-of-drug-impacting-gene-variants-found-in-all-of-us-cohort/">High Frequency of Drug-Impacting Gene Variants Found in &lt;i&gt;All of Us&lt;/i&gt; Cohort</a> appeared first on <a href="https://www.genengnews.com">GEN - Genetic Engineering and Biotechnology News</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Neuroprotective Protein Atlas Positions the Blood-Brain Barrier as a Selective Checkpoint</title>
		<link>https://www.genengnews.com/topics/translational-medicine/neuroprotective-protein-atlas-positions-the-blood-brain-barrier-as-a-selective-checkpoint/</link>
		
		<dc:creator><![CDATA[Uduak Thomas]]></dc:creator>
		<pubDate>Thu, 12 Nov 2026 18:59:49 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<category><![CDATA[OMICs]]></category>
		<category><![CDATA[Topics]]></category>
		<category><![CDATA[Translational Medicine]]></category>
		<guid isPermaLink="false">https://www.genengnews.com/?p=340568</guid>

					<description><![CDATA[<p>The blood-brain barrier keeps most proteins in the bloodstream out of the brain, but not all. The pathways that import them are damaged early in Alzheimer’s disease models, hinting at new ways to treat the disease.</p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/neuroprotective-protein-atlas-positions-the-blood-brain-barrier-as-a-selective-checkpoint/">Neuroprotective Protein Atlas Positions the Blood-Brain Barrier as a Selective Checkpoint</a> appeared first on <a href="https://www.genengnews.com">GEN - Genetic Engineering and Biotechnology News</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p><span style="font-weight: 400;">Working in mice, scientists from the Gladstone Institutes, University of California, and elsewhere have created what they claim is the first atlas of neuroprotective proteins that are transported across the blood-brain barrier and into the brain. According to the scientists, the atlas contains 92 proteins so far and their analysis points to potential strategies for treating neurodegenerative conditions. Details are provided in a new </span><i><span style="font-weight: 400;">Cell </span></i><span style="font-weight: 400;">paper titled “</span><a href="https://www.cell.com/cell/fulltext/S0092-8674(26)01326-7" target="_blank" rel="noopener"><span style="font-weight: 400;">The blood-brain barrier imports diverse neuroprotective proteins through pathways impaired early in Alzheimer’s disease models</span></a><span style="font-weight: 400;">.”</span></p>
<p><span style="font-weight: 400;">The study suggests that the blood-brain barrier is much more than a physical boundary intended solely to protect the brain from toxins. As Andrew Yang, PhD, a Gladstone investigator and one of the authors on the study put it, “we’re finding that it’s an intelligent interface that plucks the right proteins in the blood, often from distant parts of the body and delivers them to the right cell types in the brain.” Importantly, as the paper’s title suggests, the proteins included in the atlas make their way into the brain through pathways that are impaired early on in the development of diseases like Alzheimer’s.</span></p>
<p><span style="font-weight: 400;">To generate the atlas, Yang and his colleagues developed a method of tracking the specific blood plasma proteins that crossed into the brains of mice. They used protein-labeling chemistry to track proteins from multiple organs such as the liver and kidney without disrupting their biology. Specifically, they developed “a bioorthogonal proteomics strategy, an <em>in vivo</em> click-enrichment screen of labeled plasma proteins entering the brain” and used it to systematically map the blood-brain barrier “transportome,” according to the paper. The approach was benchmarked against a commonly used biotin labeling approach and was shown to consistently produce “stronger signals in plasma and brain vessels” as well as to enable “robust detection of plasma proteins in neurons, astrocytes, and microglia.” </span></p>
<p><span style="font-weight: 400;">The scientists used the method to tag various mouse blood proteins before injecting them back into the bloodstream. They examined brain tissue to see which labeled proteins successfully crossed the barrier. Of the 861 proteins that the scientists tracked in this way, they found that 92 crossed into the brain. Most were proteins produced primarily in the liver but also in adipose tissue and the intestine. Once there, the proteins were directed to specific types of brain cells to perform specialized functions. </span></p>
<p><span style="font-weight: 400;">An example is the liver protein apolipoprotein AI or (APOA1) that once in the brain activates a pathway needed to maintain healthy astrocyte connections. Studies link its absence to a greater risk of developing Alzheimer’s disease. “We think of blood proteins as messengers carrying signals from distant body parts, and the cells of the blood-brain barrier import only the ones the brain really needs,” said Haoyue Zhou, PhD, a postdoctoral scholar in Yang’s lab and first author of the paper.</span></p>
<p><span style="font-weight: 400;">A key part of the study was exploring what happens to protein delivery in Alzheimer&#8217;s. As the disease progresses, the blood-brain barrier breaks down allowing harmful proteins to leak into the brain. Using their protein-labeling method, Yang’s team discovered another problem. They found that even before the barrier breaks down, it stops importing protective proteins like APOA1 into the brain. Loss of the protein erodes neuronal connections, which contributes to behavioral changes and other early signs of the disease. </span></p>
<p><span style="font-weight: 400;">Conceivably, increasing the supply of APOA1 to the brain could help counter the emergence of Alzheimer&#8217;s symptoms. To discover whether this might be possible, the scientists tracked proteins in mouse models engineered to produce extra APOA1 in the liver. And indeed they found that as more APOA1 entered the brain, the mice showed fewer signs of the disease. These findings suggest that &#8220;Alzheimer&#8217;s disease may not start entirely inside the brain” but “when the brain’s supply line from the body is severed,” Yang noted. “If that’s right, we may be able to fight this disease from outside the brain, by restoring what the brain has lost.”</span></p>
<p><span style="font-weight: 400;">Boosting production of beneficial proteins like APOA1 to ensure the brain has a sufficient supply is one possible treatment strategy. Another option is harnessing the brain’s natural “ZIP code” system to deliver therapies directly to specific types of brain cells. A third option that Yang and his colleagues are currently exploring is harnessing the blood-brain barrier’s transport machinery to help drugs reach the brain more efficiently. </span></p>
<p>The post <a href="https://www.genengnews.com/topics/translational-medicine/neuroprotective-protein-atlas-positions-the-blood-brain-barrier-as-a-selective-checkpoint/">Neuroprotective Protein Atlas Positions the Blood-Brain Barrier as a Selective Checkpoint</a> appeared first on <a href="https://www.genengnews.com">GEN - Genetic Engineering and Biotechnology News</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>How Breast Cancer Chemotherapy May Impact Biological Aging and Loss of Healthy Life Years</title>
		<link>https://www.genengnews.com/topics/cancer/how-breast-cancer-chemotherapy-may-impact-biological-aging-and-loss-of-healthy-life-years/</link>
		
		<dc:creator><![CDATA[Sophia Ktori]]></dc:creator>
		<pubDate>Tue, 10 Nov 2026 17:26:51 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Topics]]></category>
		<category><![CDATA[Translational Medicine]]></category>
		<guid isPermaLink="false">https://www.genengnews.com/?p=340534</guid>

					<description><![CDATA[<p>Chemotherapy helps many women survive breast cancer, but the results of new research suggest that chemotherapy may also accelerate biological aging beyond chronological age and increase the risk of earlier death from other causes. </p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/how-breast-cancer-chemotherapy-may-impact-biological-aging-and-loss-of-healthy-life-years/">How Breast Cancer Chemotherapy May Impact Biological Aging and Loss of Healthy Life Years</a> appeared first on <a href="https://www.genengnews.com">GEN - Genetic Engineering and Biotechnology News</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Chemotherapy helps many women survive breast cancer, but the results of new research suggest that chemotherapy may also accelerate biological aging beyond chronological age and increase the risk of earlier death from other causes.  The study, by researchers at Georgetown University’s Lombardi Comprehensive Cancer Center and colleagues, is the first to estimate the lifetime balance of the benefits of curing breast cancer versus possible acceleration of biological aging using population-based simulation modeling. The findings point to a need to explore whether interventions to slow or reverse biological aging could improve long-term health for breast cancer survivors.</p>
<p>“Female breast cancer survivors comprise the single largest segment of the 18.6 million cancer survivors in the United States, said Jeanne Mandelblatt, MD, MPH, director of the Georgetown Lombardi’s Institute for Cancer and Aging Research (I-CARE). “However, some forms of chemotherapy that extend survival have triggered a secondary crisis: treatment-induced molecular damage to the body’s cells and organs, causing acceleration of biological age.” Mandelblatt notes that this accelerated biological aging can result in loss of healthy life years due to earlier onset of aging diseases and conditions like frailty and cognitive problems. “Chemotherapy-induced biologic aging can persist for years, and the effects of this acceleration are not visible for many years.”</p>
<p>Senior author Mandelblatt, together with first and corresponding author Swarnavo Sarkar, PhD, a member of I-CARE at Lombardi, and colleagues reported their findings in <em>JAMA Open Network</em>, titled “<a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2856363?resultClick=3" target="_blank" rel="noopener">Chemotherapy-Induced Biological Age Acceleration and Lifetime Outcomes in Breast Cancer Survivors</a>.” In their report the investigators concluded “These findings suggest that integrating knowledge about biological aging into survivorship care may help identify opportunities to deploy pharmaceutical and behavioral interventions that target aging-related processes.”</p>
<p>While breast cancer survival rates have been steadily increasing over time due to advances in screening and therapeutics, growing evidence also suggests that some breast cancer survivors may experience long-term toxic effects of chemotherapy, including accelerated aging (biological age in excess of chronological age), the authors wrote. This may be associated with the development of chronic aging-related diseases such as cardiovascular disease and diabetes.</p>
<p>“One mechanism by which chemotherapy accelerates aging is through increases in the accumulation of senescent cells, defined as cells that have stopped dividing but are resistant to cell death,” the team continued. “These cells promote further aging through changes in tissue modeling and inflammation, contributing to excess non–breast cancer morbidity and mortality.”</p>
<p>To investigate the potential long-term effect of cancer therapy on the biological aging of breast cancer survivors the team carried out a comparative effectiveness study that used an established population-level simulation model, and current data on chemotherapy’s effects on cellular senescence. “This comparative effectiveness study used an established Cancer Intervention and Surveillance Modeling Network breast cancer model integrating biological aging with breast cancer epidemiology,” they wrote.</p>
<p>The investigators used data about the relationships between chemotherapy and blood levels of the <em>p16 </em>protein, a common biomarker of senescence, to estimate the biological age of breast cancer survivors over their remaining lives. “Biological aging was modeled using data on distributions of post-chemotherapy senescence measured by <em>p16<sup>INK4a</sup></em> levels, and the model assumed chemotherapy-induced senescence only affected non–breast cancer mortality,” they explained. The <em>p16</em> protein levels were used for this study because there is good data from published research and there is evidence from the lab that clearing <em>p16</em>-rich cells could increase their lifespan. There are also evolving studies of other biological aging markers that could be used in future studies.</p>
<p>The population simulation model the researchers developed was based on women who were 30 to 79 years of age; the model compared the effects of types of chemotherapy that caused more vs. less cellular damage (i.e., cytotoxic) and biological age acceleration. Breast cancer survivors who received the most cytotoxic anthracycline regimens were estimated to have lost 9.4 remaining life years on average due to earlier onset of aging-related diseases. “Survivors diagnosed at early ages and/or treated with the most cytotoxic regimens were projected to have the greatest biological age acceleration, with increased risk of death from non–breast cancer causes at earlier chronological ages than expected in general populations,” the researchers stated.</p>
<p>Sarkar added. “The key to our methodology is accounting for the fact that while chemotherapy improves breast cancer survival, treatment can also increase damage to normal tissues. This affects many aging systems, including increasing the number of senescent cells, which are damaged cells that have stopped dividing and are also resistant to cell death. Senescent cells secrete biological molecules that cause several aging-related diseases through added tissue damage and inflammation.”</p>
<p>The data analysis was possible because both Mandelblatt and Sarkar are members of CISNET (Cancer Intervention and Surveillance Modeling Network), a 25-year-old consortium of National Cancer Institute-sponsored investigators who use simulation modeling to improve the understanding of cancer prevention, screening, and treatment and their effects on population trends in incidence and mortality.</p>
<p>While treatment choices will always be based on the potential to cure, Mandelblatt hopes that the model results can be used to guide future studies evaluating the benefits of testing biological age after treatment ends. “Since the goal of treatment is to improve breast cancer survival, oncologists should not modify treatment decisions based on potential for accelerated aging, but our results suggest the need for awareness of possible age acceleration,” the researchers pointed out.</p>
<p>The goal would be to provide personalized survivorship care to mitigate any aging effects of therapy and improve quality of life and health over a survivor&#8217;s lifetime. This is particularly salient now, Mandelblatt noted, since physical activity and medications being used for other purposes show promise in slowing accelerated aging in breast and other cancer survivors, which may recoup the loss of life years estimated in this study.</p>
<p>And as the authors also stated, more research is needed to test the impact of biological age assessment and management of biological age acceleration on survivorship outcomes. “Knowledge about the risks of accelerated aging among women exposed to chemotherapy may help motivate lifestyle changes,” they stated. “Further, as evidence on the safety and utility of senolytic and other anti-aging drugs evolves, modeling may help identify populations of survivors at risk for age acceleration who might benefit from pharmacologic intervention.”</p>
<p>Sarkar added, “There are two next steps we are planning, the first being expanding the scope of this methodology for other types of breast cancer treatments, such as radiotherapy, immunotherapies, targeted therapies and hormonal treatments, which also appear to speed up aging, with effects potentially lasting for many years after treatment. We also plan to include information about survivor characteristics to help guide future conversations about individual outcomes.”</p>
<p>The post <a href="https://www.genengnews.com/topics/cancer/how-breast-cancer-chemotherapy-may-impact-biological-aging-and-loss-of-healthy-life-years/">How Breast Cancer Chemotherapy May Impact Biological Aging and Loss of Healthy Life Years</a> appeared first on <a href="https://www.genengnews.com">GEN - Genetic Engineering and Biotechnology News</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
